Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

VBH

- PMLiVE

Novartis’ ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease

Approximately half of those with Sjögren’s disease are thought to be undiagnosed

- PMLiVE

Novartis agrees to lower drug prices in deal with US government

In 2025, the pharma company announced a $23bn US investment commitment

- PMLiVE

Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment

Around 9,000 people in the US currently live with SMA

- PMLiVE

Novartis announces plans for new US manufacturing hub

The US hub is expected to create 700 new jobs by 2030

- PMLiVE

Novartis reports primary endpoint reached in phase 3 malaria trial

The treatment demonstrated non-inferiority to current standard of care

- PMLiVE

Europe Celebrates the Heart of Healthcare Decision-Making as Laboratory Medicine Professionals Take Centre Stage

Today, the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) proudly marks European Laboratory Day, celebrating the professionals at the heart of healthcare decision making. Across Europe, laboratories will...

EatMoreFruit

- PMLiVE

Novartis presents new positive data for rheumatic autoimmune disease treatment

Patient outcome benefits were observed in two ongoing phase 3 trials

- PMLiVE

Novartis to acquire Avidity Biosciences in deal worth $12bn

The acquisition will expand Novartis’ neuroscience pipeline

Young girl receives vaccine jab in her arm

Regaining trust in childhood vaccines: can better comms turn the tables on hesitancy and misinformation?

In the wake of Trump questioning MMR vaccines, we review the best practices in vaccine communications and consider how to reverse damage done to public trust in childhood vaccinations.

Say Communications

- PMLiVE

Shifting the Paradigm: A New Era for Parkinson’s Care

In this episode of “Hear From Her:” Hear from two leaders at the forefront of a much-needed change in how Parkinson’s is understood, diagnosed, and treated.

Medscape Education

- PMLiVE

Novartis announces new data supporting MS therapy Kesimpta

The latest trial results reinforce the drug's long-term efficacy and safety profile

- PMLiVE

Novartis to acquire Tourmaline Bio in a deal worth $1.4bn

Novartis will gain cardiovascular treatment option pacibekitug

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links